Regina Robinson
Family · Nederland, TXNPI 1134477052
Payments from drug & device makers
Across 173 payments — averaging $23.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$2K
- AbbVie$913
- Madrigal Pharmaceuticals$555
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$230
- Intercept Pharmaceuticals, Inc.$133
- Intra-sana Laboratories$129
- plus $153 from 7 others
What the payments were for
- Food & beverage$4,05799%
- Education$401%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 78 | $1,983 |
| AbbVie | 49 | $913 |
| Madrigal Pharmaceuticals | 17 | $555 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 15 | $230 |
| Intercept Pharmaceuticals, Inc. | 4 | $133 |
| Intra-sana Laboratories | 2 | $129 |
| Axsome Therapeutics, Inc. | 2 | $37 |
| Ipsen Biopharmaceuticals, Inc | 1 | $24 |
| Merck | 1 | $23 |
| Novo Nordisk | 1 | $20 |
| Orphalan Inc | 1 | $19 |
| Aimmune Therapeutics, Inc. | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Epclusa$115
How this compares
$4,096 in reported general payments places this provider in the 90th percentile of 15,456 family providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EpclusaSofosbuvir/Velpatasvir | 18 | $455,930 |
| XifaxanRifaximin | 53 | $192,452 |
| Ursodiol | 192 | $13,849 |
| EliquisApixaban | 12 | $7,015 |
| Lactulose | 131 | $5,443 |
| CholestyramineCholestyramine (With Sugar) | 18 | $1,980 |
| Budesonide DrBudesonide | 19 | $1,656 |
| Entecavir | 31 | $1,537 |
| ConstuloseLactulose | 57 | $1,230 |
| Hydroxyzine Hcl | 26 | $890 |
| Ondansetron OdtOndansetron | 27 | $758 |
| Spironolactone | 59 | $634 |
| Amiloride Hcl | 18 | $624 |
| EnuloseLactulose | 28 | $454 |
| Pantoprazole Sodium | 47 | $443 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadEpclusa | $1,983 | $455,93018 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $230 | $192,45253 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 15,456 family providers in Texas.
Other family in Nederland
- Lashonda CraneHouston$3.4M
- David WeirDallas$959K
- Luba YammineHouston$479K
- Robin BeachHouston$428K
- Nirupama JeromeAustin$418K
- April LopezMcAllen$417K
- Linda MercadoHouston$211K
- Sarah AguilarHouston$199K
- Sie ThomasDallas$197K
- Anna CastroSan Antonio$184K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.